Can pharmacogenetics help rescue drugs withdrawn from the market?
about
microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentTissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screeningDrug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the MarketA cell-based biosensor for real-time detection of cardiotoxicity using lensfree imaging.A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.Machine learning plus optical flow: a simple and sensitive method to detect cardioactive drugsBioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip.Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database.A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.Modeling liver-related adverse effects of drugs using knearest neighbor quantitative structure-activity relationship method.Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channelsAsparagine synthetase: a new potential biomarker in ovarian cancer.Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting.Model-based evaluation of drug-induced QTc prolongation for compounds in early development.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?An optical multi-sensing system for detection of cardiovascular toxicity.Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk.A comparative analysis of protein targets of withdrawn cardiovascular drugs in human and mouseGenetic variation in the cysteine biosynthesis pathway causes sensitivity to pharmacological compoundsComprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System.Routine pharmacogenetic testing in clinical practice: dream or reality?Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year periodA combined-cross analysis reveals genes with drug-specific and background-dependent effects on drug sensitivity in Saccharomyces cerevisiae.Modification of distinct ion channels differentially modulates Ca2+ dynamics in primary cultured rat ventricular cardiomyocytes.Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing riskInteractions between herbal remedies and medicinal drugs--considerations about Cuba.The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels.Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives.QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review.Human stem cell-derived cardiomyocytes in cellular impedance assays: bringing cardiotoxicity screening to the front line.In silico prediction of hERG inhibition.Cardiomyopathy in a dish: using human inducible pluripotent stem cells to model inherited cardiomyopathies.The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation.Pleiotropic mechanisms of action of perhexiline in heart failure.
P2860
Q26778918-B48C9FCC-FE35-464B-85C2-E795DAEEDC76Q26799470-4D03F503-85E8-4DFD-8232-2A2216600ED7Q27006580-EA6592D6-7B50-4F1D-BB14-EF27F447EBAFQ28068710-0A54FD2A-4033-460B-9BF5-1FC138CF067EQ28554426-E6AD525A-7163-4B86-A48A-9010F540BC3FQ30538150-AF314F12-8D9D-4D48-B082-E055C5A17531Q30585177-F9C2DBD4-66AD-4508-BD86-B99EE836687DQ30656460-DE652348-7DBE-47CD-9BA3-4C68EB6C919AQ30833397-75D5583E-F552-442F-8404-9DE5DD563746Q30852962-F670AE62-A7DF-4B5A-BAD2-49596AB382ACQ33479407-38923CEB-E90F-4941-8C2C-87CFD14CE7CEQ33535332-887486D1-02F1-4B34-9CEB-AA415272E6F6Q33833264-95E15A77-5DC0-4C5D-B869-21817BBF54B8Q33894413-CAFAD86C-5220-4DA8-9CBA-CCFC33FE4A98Q34165511-9C1B845A-AE54-4224-B786-2BDBD49458FBQ34407398-0A66B12A-AEAE-47FD-B55D-135CCEABC388Q34953730-2B802643-85BD-4E95-816F-C766057C4C97Q35036150-2F47279D-AFCB-495F-AB48-645D370E989BQ35101016-9A1BCC92-B952-4128-B60C-512F0D91A089Q35819331-E1831573-869B-4BCC-BB91-563C0BDF2A24Q36146270-07EE1044-F1D4-427E-8234-2A4F42A1BD60Q36288606-EC94E32E-6849-447A-B0AF-C8E061768735Q36745692-D2E6FE27-8B58-4A4F-A01D-5BD802C1269BQ36989859-BD152683-6653-4290-A0DA-5C4534328B16Q37156289-8DD969B9-7608-4812-AE8D-C85D4881CF36Q37424977-D4AB0F97-D41E-4ECB-AFC1-CEF7386B544BQ37593391-F8452EC7-684B-4217-921A-280A9C5A53B6Q37649640-0FA2AE9C-EC26-4AB2-8C9A-0F06E6E26AAEQ37689202-8038B2A3-9ADB-4B14-82C4-8343FDBFEB8BQ37735092-BF1FDB86-518F-43A2-89DC-EFDE93DCBA22Q37838120-449615BA-97EA-4216-BBE6-9AEE164EDEAAQ38074715-1C8C2E27-7FC7-4FF9-8556-4486DEC3C58DQ38082420-56F2E1BE-C274-4F80-A9EA-C47965FFF308Q38101884-BE7CE170-866A-4E32-A9BE-52B9D6CF9E41Q38223668-21825C3C-A8FD-4002-AA07-C8000D651595Q38240972-65056863-1C27-4499-8097-74FFDE3CA3A0Q38447279-EC088BDD-B3FE-4BAD-9296-1421D3B45B8FQ38454536-875BCC06-F44F-43C1-83D7-8D7E023A3EADQ38464750-C0D86346-8ACB-4219-9156-AB34789861C8Q38907804-366DCA4F-26AB-444F-BD1F-6818CD232746
P2860
Can pharmacogenetics help rescue drugs withdrawn from the market?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Can pharmacogenetics help rescue drugs withdrawn from the market?
@ast
Can pharmacogenetics help rescue drugs withdrawn from the market?
@en
type
label
Can pharmacogenetics help rescue drugs withdrawn from the market?
@ast
Can pharmacogenetics help rescue drugs withdrawn from the market?
@en
prefLabel
Can pharmacogenetics help rescue drugs withdrawn from the market?
@ast
Can pharmacogenetics help rescue drugs withdrawn from the market?
@en
P2860
P356
P1433
P1476
Can pharmacogenetics help rescue drugs withdrawn from the market?
@en
P2093
Rashmi R Shah
P2860
P304
P356
10.2217/14622416.7.6.889
P577
2006-09-01T00:00:00Z